Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 14/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 13/20 | 0.51 |
| ▸ | EGFR | P00533 | 4/20 | 0.51 |
| ▸ | KDR | P35968 | 4/20 | 0.51 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.51 |
| ▸ | LCK | P06239 | 2/20 | 0.51 |
| ▸ | LYN | P07948 | 2/20 | 0.51 |
| ▸ | RET | P07949 | 2/20 | 0.51 |
| ▸ | HCK | P08631 | 2/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.51 |
| ▸ | KIT | P10721 | 2/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.51 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.51 |
| ▸ | FLT3 | P36888 | 2/20 | 0.51 |
| ▸ | MST1R | Q04912 | 2/20 | 0.51 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.51 |
| ▸ | AURKC | Q9UQB9 | 2/20 | 0.51 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.51 |
| ▸ | FYN | P06241 | 1/20 | 0.51 |
| ▸ | RAB6A | P20340 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13399744 | 0.91 | AURKA (0.56) | AURKAAURKBEGFRKDRRIPK2 | |
| SCHEMBL13399741 | 0.84 | AURKA (0.74) | AURKAAURKBEGFRKDRRIPK2 | |
| SCHEMBL13399746 | 0.80 | AURKA (0.66) | AURKAAURKBEGFRKDRRIPK2 | |
| SCHEMBL13399801 | 0.76 | AURKB (0.59) | AURKAAURKBEGFR | |
| SCHEMBL13399743 | 0.75 | AURKA (0.79) | AURKAAURKBEGFRKDRRIPK2 | |
| SCHEMBL13399798 | 0.74 | AURKA (0.76) | AURKAAURKBEGFRKDRRIPK2 | |
| SCHEMBL13399738 | 0.73 | AURKA (0.69) | AURKAAURKBEGFRKDR | |
| SCHEMBL13399963 | 0.73 | MAPK1 (0.65) | AURKAAURKBEGFRKDRLCK | |
| SCHEMBL13399748 | 0.72 | AURKA (0.56) | AURKAAURKBEGFRKDRRIPK2 | |
| SCHEMBL20078516 | 0.72 | AURKA (0.59) | AURKAAURKBEGFRKDRRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006252-B2 | Fused multicyclic compounds as protein kinase inhibitors | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2015-04-14 | — | — | US | disclosed |
| US-9006252-B2 | Fused multicyclic compounds as protein kinase inhibitors | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2015-04-14 | — | — | US | disclosed |
| EP-2331530-B1 | FUSED MULTICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | NAT HEALTH RESEARCH INSTITUTES (CN) | 2013-08-21 | — | — | EP | disclosed |
| WO-2010036629-A2 | FUSED MULTICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-04-01 | — | — | WO | disclosed |
| US-20100081675-A1 | FUSED MULTICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-04-01 | — | — | US | disclosed |
| US-20100081675-A1 | FUSED MULTICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081675-A1 | FUSED MULTICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | AURKC, AURKA, AURKB | AURKA 2/4885AURKB 3/4885EGFR 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.